Related Experiment Video
Updated: Mar 11, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
28.0K
Radiation maculopathy treated with intravitreal bevacizumab
J L Sánchez-Vicente1, A Muñoz-Morales1, M P Galván-Carrasco1
1Unidad de Gestión Clínica de Oftalmología, Hospital Universitario Virgen del Rocío, Sevilla, España.
Archivos De La Sociedad Espanola De Oftalmologia
|November 30, 2016
Summary
Intravitreal Bevacizumab effectively treated radiation-induced macular edema secondary to choroidal melanoma. This treatment led to reduced swelling and improved vision, with sustained results over three years.
Area of Science:
- Ophthalmology
- Oncology
- Medical Imaging
Background:
- Choroidal melanoma is a rare intraocular malignancy.
- Radiation therapy, including brachytherapy plaque, is a common treatment for choroidal melanoma.
- Macular edema can occur as a secondary complication of radiation therapy for choroidal melanoma.
Observation:
- A 47-year-old woman developed macular edema 75 months post-brachytherapy for choroidal melanoma.
- The patient received three intravitreal injections of Bevacizumab.
Findings:
- Bevacizumab treatment resulted in a significant reduction in macular edema, as evidenced by optical coherence tomography (OCT) scans.
- Best corrected visual acuity improved following Bevacizumab injections.
- The positive effects, including reduced edema and stable visual acuity, were maintained during a three-year follow-up period without recurrence.
Implications:
- Intravitreal Bevacizumab is a viable therapeutic option for managing radiation-induced macular edema in patients with a history of choroidal melanoma.
- This approach may help preserve or improve visual function in patients experiencing vision loss due to treatment complications.
- Long-term monitoring is essential to ensure sustained efficacy and detect any potential recurrence.
